Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | INPP5A | Q14642 | 3/20 | 0.35 |
| ▸ | UPP1 | Q16831 | 1/20 | 0.33 |
| ▸ | ITPR2 | Q14571 | 1/20 | 0.33 |
| ▸ | ITPR3 | Q14573 | 1/20 | 0.33 |
| ▸ | ITPR1 | Q14643 | 1/20 | 0.33 |
| ▸ | FBP1 | P09467 | 1/20 | 0.33 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14364674 | 0.87 | FBP1 (0.47) | FBP1P2RY1 | |
| SCHEMBL16674740 | 0.86 | INPP5A (0.34) | INPP5AUPP1ITPR2ITPR3ITPR1 | |
| SCHEMBL18054951 | 0.83 | INPP5A (0.37) | INPP5AITPR2ITPR3ITPR1 | |
| SCHEMBL271833 | 0.80 | P2RY2 (0.37) | P2RY1 | |
| SCHEMBL10005833 | 0.75 | — | — | |
| SCHEMBL15806353 | 0.75 | — | — | |
| SCHEMBL16674741 | 0.75 | — | — | |
| SCHEMBL10018595 | 0.75 | — | — | |
| SCHEMBL15905936 | 0.74 | — | — | |
| SCHEMBL15788841 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11597745-B2 | β-modified phosphoric acid compound precursor, β-modified phosphoric acid compound, reaction inhibitor and medicine containing the same, and method for inhibiting reaction | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2023-03-07 | — | — | US | disclosed |
| US-20210284679-A1 | ß-Modified Phosphoric Acid Compound Precursor, ß-Modified Phosphoric Acid Compound, Reaction Inhibitor and Medicine Containing the Same, and Method for Inhibiting Reaction | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2021-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11597745-B2 | β-modified phosphoric acid compound precursor, β-modified phosphoric acid compound, reaction inhibitor and medicine containing the same, and method for inhibiting reaction | PPM1A, PPM1G, PPM1F | INPP5A 227/4885UPP1 336/4885ITPR2 917/4885 |
| US-20210284679-A1 | ß-Modified Phosphoric Acid Compound Precursor, ß-Modified Phosphoric Acid Compound, Reaction Inhibitor and Medicine Containing the Same, and Method for Inhibiting Reaction | IRS1, PPM1A, PPM1G | INPP5A 203/4885UPP1 309/4885ITPR2 566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.